BSEEiko Lifesciences LtdMinimalNeutral
Announced Wed, 27 May · 11:32 IST

Newspaper publication dated 27th May, 2026 for Audited Financial Results (Standalone & Consolidated) of the Company for the Quarter and Year ended 31st March, 2026 approved by the Board ....

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-2.5%1-day move
₹53.48
prior close
₹54.90
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-2.4-2.4-2.4-0.4-2.5-1.6-0.3-3.4-7.1-0.9-2.8-6.5-8.0
Up moveDown movePending
AI summary

Eiko Lifesciences Ltd published its audited financial results for Q4 and the full year ended March 31, 2026. The Board of Directors approved the results at their meeting on May 26, 2026. For the standalone entity, Q4 FY26 total income stood at Rs. 4,425.61 lakhs with net profit of Rs. 471.30 lakhs, while FY26 full-year total income was Rs. 5,367.94 lakhs with net profit of Rs. 706.47 lakhs. Consolidated Q4 FY26 net profit was Rs. 149.33 lakhs compared to Rs. 85.46 lakhs in Q4 FY25, representing a ~75% year-on-year increase in quarterly net profit. The results were published in Mumbai Lakshadeep (Marathi) and Financial Express (English) newspapers on May 27, 2026, as per SEBI LODR Regulations 30 and 47.

Likely market impact

Strong year-on-year profit growth signals operational improvement. The ~75% YoY jump in Q4 net profit and full-year net profit nearly tripling from Rs. 258.04 to Rs. 706.47 lakhs is a positive indicator for shareholders, reflecting better operational efficiency.